BioMedNewsBreaks

WednesdayDec 09, 2020 1:00 pm

BioMedNewsBreaks – LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) to Participate at LD Micro Main Event

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced that Dr. Jack Regan, LexaGene’s CEO and founder, will present at the 13th Annual LD Micro Main Event Conference. Interested parties should visit https://ibn.fm/tKpNj to register for the event, slated to be held on Dec. 15, 2020. In addition, the company announced that it has engaged Native Ads Inc. of New York to perform strategic digital media, marketing and data analytics services including, but not limited to, content development, video production and editing, website development, media buying and distribution, and campaign…

Continue Reading

WednesdayDec 09, 2020 11:46 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Describes ‘Most Exciting Thing That I’ve Done’ on Gamechangers LIVE

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently appeared on Gamechangers LIVE, a podcast series that shines a spotlight on gamechangers in various industries, sharing perspective on journeys, mindsets, struggles and successes in an effort to inspire and inform listeners. During the interview, CNSP’s chairman and CEO, John Climaco, provided an overview of CNS Pharmaceuticals and its lead drug candidate, Berubicin. Proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer, Berubicin was evaluated in…

Continue Reading

WednesdayDec 09, 2020 10:49 am

BioMedNewsBreaks — MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Announces Live Investor Webcast; Provides Overview of Biopesticide Pipeline

MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) has provided an update of its natural plant-based, mustard-derived biopesticide technology product pipeline. The company is intent on using the natural defense mechanism of the mustard seed to develop and commercialize biopesticide technologies; MustGrow is using the technology to control diseases, pests and weeds. The company is planning a live investor webcast today to discuss upcoming catalysts; the webcast is slated to begin at 11 a.m. ET. Anyone interested in attending should sign in five minutes early. Participants will be anonymous and muted, but questions can be sent to the company (info@mustgrow.ca) before…

Continue Reading

TuesdayDec 08, 2020 2:15 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Shines Spotlight on Clinical Design for Upcoming Phase 2 Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, is advancing a drug candidate it hopes will beat the deadly brain cancer Glioblastoma Multiforme (“GBM”). The company recently announced that its submission of an Investigational New Drug (“IND”) application to the U.S. Food & Drug Administration (“FDA”) has been accepted for review and discussed a novel clinical design for its upcoming Phase 2 U.S. trial in a webinar open to the public. “I would like to remind everyone that this upcoming Phase 2…

Continue Reading

TuesdayDec 08, 2020 1:58 pm

BioMedNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Soluble Biotech Solution Shaves Time, Money to Optimize Therapeutic Formulations

Predictive Oncology (NASDAQ: POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery. Through its subsidiary Soluble Biotech, the company delivers a solution that reduces the cost, time and manpower needed to optimize therapeutic formulations. A recent article discussing this reads, “HSC Technology is a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens, using additives and excipients commonly included in protein formulations (https://ibn.fm/QPo4W). The data generated from these screens is analyzed by a predictive algorithm used to identify the optimal combination of additives and excipients, resulting in increased…

Continue Reading

TuesdayDec 08, 2020 11:15 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Finalizes Technology Transfer of Manufacturing Process for Novel Gene Therapy

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has reached a significant milestone. The company successfully completed the technology transfer of its manufacturing process for the production of its lead candidate for immunogene therapy, REQORSA(TM). The transfer was made from the major cancer research institution where it had previously been manufactured to experienced, commercial contract development and manufacturing organizations (“CDMOs”). This step marks the first time REQORSA has been manufactured outside of the research institution where it was discovered and at commercial scale in a current Good Manufacturing Practices (“cGMP”)-compliant…

Continue Reading

MondayDec 07, 2020 10:10 am

BioMedNewsBreaks – MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Announces Upcoming Investor Webcast

MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural biological crop protection for high value crops, today announced an upcoming live webcast for its investment community. According to the update, MustGrow is poised to capitalize in 2021 and beyond in a rapidly growing market as regulatory framework moves to favor organic biopesticides and bioherbicides. The webcast is scheduled to take place at 11:00 a.m. ET on Wednesday, Dec. 9, 2020. Interested parties may visit https://ibn.fm/9Jz3E to register for the event and are asked to join five minutes before the beginning of the webcast. To view…

Continue Reading

FridayDec 04, 2020 11:11 am

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) to Showcase NeuroCap(TM) at AES2020

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, today announced that it will participate in AES2020 – the all-new virtual event for epilepsy professionals in academia, clinical practice, industry and advocacy. Slated to take place on Dec. 4–8, 2020, the American Epilepsy Society's Annual Meeting is the largest meeting and exhibition in the world to share common scientific and clinical interests in epilepsy and clinical neurophysiology. “Brain Scientific has successfully taken part in AES conferences before, and this year we will have a virtual booth at this important event. We will be showing the new version of…

Continue Reading

ThursdayDec 03, 2020 3:25 pm

BioMedNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Present at LD Micro Main Event

180 Life Sciences (NASDAQ: ATNF, ATNFW), a clinical-stage biotechnology company with its lead indication in phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it will participate in the LD Micro Virtual Main Event 2020 Conference. According to the update, 180 Life Sciences CEO Dr. James Woody is scheduled to present at 1:40 p.m. EST on Tuesday, Dec. 15. Interested parties should visit https://ibn.fm/KHrgf to register for the event. The 2020 LD Micro Main Event will feature a new and unique format with companies presenting for 10…

Continue Reading

ThursdayDec 03, 2020 12:49 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present Overview, Clinical Trial Update at Upcoming Benzinga Conference

Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it will present at the Benzinga Global Small Cap Conference taking place virtually on Dec. 8-9, 2020. Genprex’s president and CEO, Rodney Varner, will deliver a company overview that includes recent progress the company has made on its upcoming Acclaim-1 clinical trial. Varner’s presentation is scheduled to begin at 2:30 p.m. EST on Tuesday, Dec. 8. Investors and other interested parties should visit https://ibn.fm/VdFrh to register for the event. To view the full press release, visit https://ibn.fm/EPK3b About Genprex Inc. Genprex is a…

Continue Reading